HAIFA, ISRAEL, Dec. 3, 2009--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced that it will present at the 7th Annual Commercial Translation of Regenerative Medicine at the NH Harrington Hall in London.  Chaya Mazouz, vice president of clinical and regulatory affairs at Pluristem, will present on developing clinical trial standardization as a process and overcoming regulatory hurdles at 9:10 a.m. BST, Friday, Dec. 4, 2009.

“Pluristem is an exemplary case study design of clinical trial standardization,” said Ms. Mazouz. “We are effectively utilizing and benefiting from the design of the trial in our Phase-I European and U.S. clinical trials, which are currently underway for the treatment of critical limb ischemia, the end stage of peripheral artery disease.”

The 7^th Annual Commercial Translation of Regenerative Medicine Regenerative Medicine focuses on a rapidly growing field of biomedicine. The conference brings together key industry, academia and regulatory experts who provide an insight into the technologies and therapies that are nearing the market. Experts from the industry present case studies focusing on the regulatory hurdles to overcome to guarantee commercial success.

About Pluristem

Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s patented and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.

See our product animation on YouTube: Animation, the content of which is not part of this press release.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.